Biofrontera, Inc. - רווח נקי למניה בארבעת הרבעונים האחרונים BFRI
High marketing costs in the US and insurance reimbursement challenges are weighing on the margins of Biofrontera Inc. (BFRI). The issuer dominates the photodynamics sector, locking clinics into the brand through a combined "device and drug" bundle. Innovative light-activated agents eliminate pathologies painlessly. The annual change in net income per share over a rolling period reflects EPS dynamics, where the value remains at 72.60.
BFRI (Biofrontera Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The reliability of equity assets is determined by the stability of profit generation per unit of capital. This metric measures net income dynamics over the last four quarters relative to the same period last year. For Biofrontera Inc. (BFRI), this calculation reflects the efficiency of the Ameluz drug commercialization and the expansion of its commercial presence. Positive YoY earnings per share growth over 12 months confirms the scaling of the business. Analysis of this chart allows for the timely identification of a trend reversal.
